Concepts (47)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 4 | 2011 | 216 | 0.740 |
Why?
|
| Lung Neoplasms | 4 | 2011 | 505 | 0.630 |
Why?
|
| Autoantibodies | 2 | 2010 | 71 | 0.420 |
Why?
|
| Early Detection of Cancer | 2 | 2010 | 85 | 0.410 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 13 | 0.360 |
Why?
|
| Hematologic Tests | 1 | 2010 | 6 | 0.360 |
Why?
|
| Protein Array Analysis | 1 | 2010 | 10 | 0.350 |
Why?
|
| Algorithms | 3 | 2010 | 358 | 0.170 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 179 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2011 | 1829 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 63 | 0.090 |
Why?
|
| Serum | 1 | 2010 | 7 | 0.090 |
Why?
|
| Pneumonectomy | 1 | 2011 | 67 | 0.090 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 13 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2010 | 38 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2010 | 80 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 230 | 0.080 |
Why?
|
| Proteomics | 1 | 2010 | 91 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 123 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 1 | 2009 | 11 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2010 | 550 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 29 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2009 | 43 | 0.080 |
Why?
|
| Adult | 3 | 2011 | 7367 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 4674 | 0.060 |
Why?
|
| Humans | 5 | 2011 | 26049 | 0.060 |
Why?
|
| Middle Aged | 3 | 2011 | 8511 | 0.050 |
Why?
|
| Aged | 3 | 2011 | 8719 | 0.050 |
Why?
|
| Male | 4 | 2011 | 14025 | 0.050 |
Why?
|
| Female | 3 | 2011 | 14411 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2011 | 3293 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 42 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 70 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 10 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 161 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2011 | 235 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 21 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 253 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 295 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 327 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 313 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2011 | 622 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1713 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2011 | 862 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2009 | 713 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1140 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3305 | 0.010 |
Why?
|